Pharvaris
PHVS | NASDAQ
$32.44
-$0.92 (-2.76%)
At close: Nov 16, 2026, 4:00 PM ET
$32.50
+$0.06 (+0.18%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Pharvaris Company Profile
Company profile explainedCompany Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director |
| David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer |
| Anne Lesage | Chief Early Development Officer |
| Annick Deschoolmeester | Chief Human Resources Officer |
| Maggie Beller | VP & Head of Corporate and Investor Communications |
| Maryann Cimino | Director of Corporate Relations |
| Peng Lu | President |
| Stefan Abele | Chief Technology Operations Officer |
| Wim Souverijns | Chief Commercial Officer |
Pharvaris
| Country | Switzerland |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 148 |
| CEO | Berndt Modig |
Stock Details
| Ticker Symbol | PHVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001830487 |
| CUSIP Number | n/a |
| ISIN Number | NL00150005Y4 |
| SIC Code | 2834 |
Recent News
- 15 hours ago / zacks.comWall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
- 4 days ago / globenewswire.comPharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
- 4 days ago / globenewswire.comPharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
- 19 days ago / globenewswire.comPharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
- 25 days ago / benzinga.comTwo Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
- 1 month ago / globenewswire.comPhase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
- 1 month ago / globenewswire.comReal-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
- 2 months ago / seekingalpha.comPharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2 months ago / zacks.comPHVS Stock Rises 10% in a Month: What Is Driving the Rally?
- 2 months ago / seekingalpha.comPharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Add to Watchlist
Select watchlists to add or remove PHVS